Hyperglycemia and Acute Pancreatitis

September 13, 2024 updated by: Tuo Li, MD, Shanghai Changzheng Hospital

The Risk Factors and Predictors of Hyperglycemia Secondary to Acute Pancreatitis

The goal of this observational study is to learn about post-acute pancreatitis diabetes mellitus (PPDM-A). The main questions it aims to answer are:

  1. What are the clinical characteristics of PPDM-A?
  2. What are the related factors for PPDM-A?

All patients with acute pancreatitis have been given standardized treatment for the condition.

The researchers will compare the PPDM-A group with the non-PPDM-A group to find the risk factors for PPDM-A.

Study Overview

Status

Completed

Conditions

Detailed Description

Investigators retrospectively collected data from patients with acute pancreatitis (AP) in participating centers between January 2013 and June 2024.

Study Type

Observational

Enrollment (Actual)

4500

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

We collected data from patients with acute pancreatitis (AP) in participating centers between January 2013 and June 2024.

Description

Inclusion Criteria:

  1. Patients with pancreatitis attending participating centers since January 2013 (patients with clinically reported AP (ICD-10:K85 or related diagnosis));
  2. Age between 18 and 80 years;
  3. Patients have undergone glucose metabolic tests at least 1 month after discharge from hospital.

Exclusion Criteria:

  1. Patients with a history of diabetes mellitus prior to the AP attack;
  2. Patients who underwent pancreatic surgery;
  3. Patients with hereditary pancreatitis and autoimmune pancreatitis;
  4. Patients with missing data regarding age or gender.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Acute pancreatitis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants who have developed PPDM-A
Time Frame: From the AP treatment to 5 years after the end of treatment
PPDM-A was defined as diabetes after AP in the absence of a history of preexisting diabetes before the AP episode.
From the AP treatment to 5 years after the end of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Shanghai Changzheng Hospital

Collaborators

Changhai Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2013

Primary Completion (Actual)

August 1, 2024

Study Completion (Actual)

August 1, 2024

Study Registration Dates

First Submitted

August 29, 2024

First Submitted That Met QC Criteria

September 5, 2024

First Posted (Estimated)

September 10, 2024

Study Record Updates

Last Update Posted (Estimated)

September 19, 2024

Last Update Submitted That Met QC Criteria

September 13, 2024

Last Verified

September 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NMU-3cDM-1A

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe